Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ociperlimab - BeOne Medicines

Next Previous
Drug Profile

Ociperlimab - BeOne Medicines

Alternative Names: Anti-TIGIT monoclonal antibody - BeOne Medicines; BGB-A1217; WCD-118

Latest Information Update: 14 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BeiGene
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cervical cancer; Diffuse large B cell lymphoma; Liver cancer; Non-small cell lung cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer

Most Recent Events

  • 12 Jun 2025 Efficacy, adverse events and pharmacokinetic data from a phase Ib/II AdvanTIG-101 trial in Diffuse large B cell lymphoma presented at the 30th Congress of the European Haematology Association (EHA-2025)
  • 18 Apr 2025 Discontinued - Phase-II for Cervical cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Russia (IV)
  • 03 Apr 2025 Discontinued - Phase-I for Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Taiwan, USA, China, Australia (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top